Pioneering TCR T cell therapy
We view Adaptimmune as one of the leaders in the TCR T space due to: i) initiated BLA submission for the lead asset, afami-cel, in synovial sarcoma, which could secure the first-ever approval for TCR-T therapy; ii) while afami-cel provided solid validation, the next generation program, ADP-A2M4CD8,
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.